二甲双胍治疗常染色体显性多囊肾病的可行性研究
这项前瞻性随机双盲安慰剂对照试验纳入51例30-60岁、无糖尿病且eGFR 50-80 mL/min/1.73 m2的ADPKD成人,评估二甲双胍(最大2000 mg/d)12个月的安全性与耐受性。主要终点为完成全剂量或至少50%随机剂量的参与者比例;二甲双胍组50%完成全剂量、82%耐受至少50%剂量,未发生乳酸酸中毒,胃肠道不良症状较多,探索性分析中htTKV与eGFR变化组间无显著差异。
要点
- ADPKD患者使用二甲双胍未发生乳酸酸中毒,安全性可接受。
- 二甲双胍组50%完成全剂量,82%耐受至少50%剂量。
- 探索性分析未显示htTKV或eGFR变化组间显著差异。
核心结论
- 在ADPKD且无糖尿病患者中,至少50%最大剂量二甲双胍治疗12个月安全且耐受良好。
研究设计与样本
- 前瞻性随机对照双盲临床试验,纳入51例30-60岁ADPKD成人,eGFR 50-80 mL/min/1.73 m2,无糖尿病。
- 干预为二甲双胍(最大剂量2000 mg/d)或安慰剂治疗12个月。
主要发现
- 二甲双胍组无乳酸酸中毒病例,每组各有1例轻度低血糖。
- 二甲双胍组报告更多不良症状,主要与胃肠道相关。
- 22例二甲双胍治疗者中11例(50%)以全剂量完成治疗阶段,安慰剂组23例中23例(100%)。
- 二甲双胍组82%参与者耐受至少50%剂量,安慰剂组为100%。
- 探索性分析中,htTKV或eGFR变化组间无显著差异。
关键数值与推荐
- 共同主要终点为12个月末各组中处方全随机剂量或至少50%随机剂量的参与者百分比。
- 次要及探索性终点包括以身高标化的总肾脏体积(htTKV,mL/m)百分比变化和12个月eGFR变化。
临床怎么用
- 在ADPKD且无糖尿病患者中可考虑使用至少50%最大剂量二甲双胍,但需关注胃肠道不良反应。
- 二甲双胍对htTKV和eGFR的疗效尚未证实,不应据此用于肾脏预后改善。
局限性
- 研究持续时间短。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Autosomal dominant polycystic kidney disease (ADPKD) is a common inherited disorder that leads to kidney failure and has few treatment options. Metformin is well tolerated and safe in other patient populations. The primary objective of this clinical trial was to determine the safety and tolerability of metformin in patients with ADPKD and without diabetes mellitus. STUDY DESIGN: Prospective randomized controlled double-blind clinical trial. SETTING & PARTICIPANTS: 51 adults aged 30-60 years with ADPKD, without diabetes, and an estimated glomerular filtration rate (eGFR) 50-80 mL/min/1.73 m2. EXPOSURE: Metformin (maximum dose 2,000 mg/d) or placebo for 12 months. OUTCOME: Coprimary end points were the percentage of participants in each group prescribed at the end of the 12-month period: (1) the full randomized dose or (2) at least 50% of the randomized dose. Secondary and exploratory outcomes were the effect of metformin compared with placebo on (1) the percentage change in total kidney volume (TKV) referenced to height (htTKV in mL/m) and (2) the change in eGFR over a 12-month period. RESULTS: The participants' mean age was 48 ± 8 (SD) years, and eGFR was 70 ± 14 mL/min/1.73 m2. The metformin group had no cases of lactic acidosis, and there was 1 episode of mild hypoglycemia in each group. Participants in the metformin group reported more adverse symptoms, mostly related to the gastrointestinal tract. Eleven of 22 metformin-treated participants (50%) completed the treatment phase on the full dose compared with 23 of 23 in the placebo group (100%). In the metformin group, 82% of participants tolerated at least 50% of the dose, compared with 100% in the placebo group. In exploratory analyses, changes in htTKV or eGFR were not significantly different between the groups. LIMITATIONS: Short study duration. CONCLUSIONS: We found that 50% or more of the maximal metformin dose was safe and well tolerated over 12 months in patients with ADPKD. Safety of other preparations of metformin as well as its efficacy should be tested in future clinical trials. FUNDING: Government and philanthropic grants (NIDDK and the Zell Foundation). TRIAL REGISTRATION: Registered at ClinicalTrials.gov with study number NCT02903511.
引用
- Brosnahan GM, Wang W, Gitomer B, et al. Metformin Therapy in Autosomal Dominant Polycystic Kidney Disease: A Feasibility Study. Am J Kidney Dis. 2021. PMID: 34391872. doi:10.1053/j.ajkd.2021.06.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。